Inventiva Sees Unusually Large Options Volume (NASDAQ:IVA)

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was the target of unusually large options trading activity on Wednesday. Traders bought 40,232 call options on the stock. This represents an increase of approximately 201,060% compared to the typical volume of 20 call options.

Inventiva Price Performance

NASDAQ IVA remained flat at $3.91 on Friday. 1,830,204 shares of the company’s stock traded hands, compared to its average volume of 1,206,806. Inventiva has a 12 month low of $2.85 and a 12 month high of $7.98. The firm has a fifty day simple moving average of $4.55 and a 200-day simple moving average of $5.32.

Inventiva (NASDAQ:IVA) last released its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $0.01 million for the quarter. On average, equities research analysts expect that Inventiva will post -0.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on IVA. Truist Financial initiated coverage on Inventiva in a research note on Thursday, March 19th. They issued a “buy” rating and a $13.00 price objective on the stock. Wall Street Zen cut Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a report on Tuesday, April 21st. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Inventiva presently has a consensus rating of “Buy” and an average target price of $16.56.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IVA. UBS Group AG lifted its stake in Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after purchasing an additional 2,634,580 shares during the last quarter. Propel Bio Management LLC purchased a new position in Inventiva in the fourth quarter valued at approximately $4,650,000. Eventide Asset Management LLC purchased a new position in Inventiva in the fourth quarter valued at approximately $1,155,000. Simplify Asset Management Inc. acquired a new stake in Inventiva during the fourth quarter worth approximately $1,570,000. Finally, NEXTBio Capital Management LP acquired a new stake in Inventiva during the fourth quarter worth approximately $6,039,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.